ANVISA Registration & Brazil Submissions at the Celesta Healthcare clinical research centre
Regulatory Affairs · Brazil & ANVISA

ANVISA Registration & Brazil Submissions

Brazil is Latin America’s largest pharmaceutical market, and its gatekeeper accepts bioequivalence data only from centres it has approved. Ours is one of them — a claim very few Indian clinical research facilities can make.

ANVISA
Approved Clinical
Facility
120
Days — Priority
Review Clock
365
Days — Standard
Review Clock
75+
Validated
Methods
Get a Proposal
All Regulatory Affairs
Overview

Registering Pharmaceuticals in Brazil

Brazil’s Agência Nacional de Vigilância Sanitária — ANVISA — is one of the most demanding regulators in the emerging-market world, and an ICH member since 2016. Registration dossiers follow a CTD-aligned structure filed electronically, review clocks are set in law at 365 days for standard applications and 120 days for priority ones, and marketing authorization must be held by an entity legally established in Brazil. For generic and similar medicines, pharmaceutical equivalence and bioequivalence against the Brazilian reference product are the heart of the application.

For Indian exporters, the practical bottleneck is bioequivalence. ANVISA accepts BE studies only from centres it has itself evaluated and approved — and that approval is rare among Indian clinical facilities. Sponsors without access to an approved centre face repeating studies in Brazil at several times the cost, or waiting on a certification process they cannot control.

This is where Celesta Healthcare is structurally different: our clinical research facility in Pune is ANVISA-approved. We design and run bioequivalence studies to ANVISA’s framework under RDC 742/2022, compile the registration dossier, and manage exigência (deficiency) responses with your Brazilian registration holder through to approval.

Registration Pathways

Generic vs Similar vs New Drug in Brazil

Brazil registers synthetic medicines in three categories, and the evidence ANVISA expects differs by pathway.

Comparison of the generic, similar, and new drug registration categories in Brazil
AspectGenericSimilarNew Drug
Brand nameNone — sold by INN (active ingredient) onlyProprietary brand nameProprietary brand name
Evidence requiredPharmaceutical equivalence + bioequivalence vs the referencePharmaceutical equivalence + relative bioavailability/bioequivalenceFull quality, safety, and efficacy dossier
InterchangeabilityInterchangeable with the reference productInterchangeable once comparability tests are approved and listedNot applicable — typically becomes the reference
Typical fitMost Indian generic exports to BrazilBranded-generic strategiesInnovator and novel products
Services

Brazil Submission Services

BE Studies for ANVISA

Bioequivalence studies designed to RDC 742/2022 and conducted at our ANVISA-approved centre in Pune.

Registration Dossier Compilation

CTD-aligned dossiers assembled to ANVISA’s structure, with Brazilian reference product strategy built in.

Registration Holder Coordination

Working alongside your Brazilian subsidiary or local partner, who legally holds and files the application.

ANVISA GMP Certification Support

Documentation and inspection readiness support for the manufacturing site certification Brazil requires.

Exigência Responses

ANVISA deficiency letters answered in structured, deadline-tracked responses through to approval.

Structural Advantage

An ANVISA-Approved Facility in India

ANVISA evaluates and approves the clinical centres whose bioequivalence data it will accept — and very few Indian facilities hold that approval. Our 17,000 sq ft clinical research centre in Pune does, alongside its DCGI mandate. Studies run there on coupled AB Sciex LC-MS/MS units against 75+ validated methods, so Brazilian submissions are built on data generated inside ANVISA’s own quality perimeter rather than argued into it afterwards.

ANVISA
Approved Centre
17,000
Sq Ft Facility
75+
Validated Methods
65+
Studies Executed
How It Runs

From Pathway to Brazilian Approval

  1. 01

    Pathway & Reference Definition

    Generic, similar, or new drug route confirmed, with the Brazilian reference product and study requirements mapped.

  2. 02

    Bioequivalence Study

    The BE study designed to RDC 742/2022 and executed at our ANVISA-approved centre, with LC-MS/MS bioanalysis in-house.

  3. 03

    Dossier Compilation

    Quality, equivalence, and study evidence compiled into ANVISA’s dossier structure, with labeling adaptation planned for Portuguese.

  4. 04

    Filing via Registration Holder

    Your Brazilian entity or partner files through ANVISA’s electronic petitioning system; we prepare everything behind the filing.

  5. 05

    Exigência Management to Approval

    Deficiency letters answered within their deadlines, review clocks tracked, and the registration carried to grant.

Why Celesta

Why Sponsors Choose Us for ANVISA / Brazil

  • Clinical research facility approved by ANVISA — rare among Indian CROs
  • BE studies designed to RDC 742/2022 from day one
  • 75+ validated LC-MS/MS methods on AB Sciex platforms
  • CTD-aligned dossiers adapted to ANVISA’s structure
  • Coordination with your Brazilian registration holder
  • Structured exigência response management to approval
FAQs

ANVISA / Brazil — Frequently Asked Questions

1. How long does ANVISA drug registration take?
Brazilian law sets ANVISA’s review clocks at 365 days for standard applications and 120 days for priority ones, extendable by up to a third. Real calendar time depends on exigência cycles — each deficiency letter pauses progress until answered — so dossier completeness at filing is the biggest lever a sponsor controls.
2. Does ANVISA accept bioequivalence studies conducted in India?
Yes — provided the study is conducted at a centre ANVISA has evaluated and approved. The agency maintains its own approval of bioequivalence centres rather than accepting any GCP facility by default. Our clinical research facility in Pune holds that ANVISA approval, so studies run there are designed for acceptance in Brazil from the outset.
3. What is RDC 742/2022?
RDC 742/2022 is ANVISA’s resolution governing bioequivalence and relative bioavailability studies — the criteria for study design, conduct, statistical analysis, and acceptance used to demonstrate equivalence with the Brazilian reference product. It replaced the earlier RE 1170/2006 framework and continues to evolve toward ICH M13 alignment.
4. Do foreign pharmaceutical companies need a local representative in Brazil?
Yes. Marketing authorization in Brazil must be held by an entity legally established in the country with ANVISA operating authorization — typically a Brazilian subsidiary or a local partner acting as the registration holder, responsible for importation, distribution, and post-market obligations. We prepare the science and the dossier; your Brazilian entity files and holds the registration.
5. Does ANVISA require the CTD format?
ANVISA has been an ICH member since 2016 and structures registration dossiers along CTD lines, filed electronically through its petitioning system. A well-built CTD core dossier therefore adapts efficiently to Brazil — the work lies in the Brazilian reference product strategy, Portuguese labeling, and market-specific annexes rather than in restructuring the evidence.
6. What is the difference between generic and similar drugs in Brazil?
Both are copies of a reference product, and both must prove pharmaceutical equivalence and bioequivalence or relative bioavailability. The commercial difference: a generic carries no brand name and is sold by INN as interchangeable with the reference, while a similar is marketed under its own brand and becomes interchangeable once its comparability tests are approved and listed.
7. Does ANVISA inspect manufacturing sites in India?
Yes. Foreign manufacturing sites supplying Brazil need ANVISA GMP certification, granted after the agency’s own inspection or through recognized reliance mechanisms. Indian sites are inspected routinely. We support the documentation and readiness work on the regulatory side so the site certification and the product registration advance in parallel rather than in sequence.

More Regulatory Affairs Services

Every study type under one roof — explore the rest of our regulatory affairs capabilities.

Regulatory Affairs Overview

Dossier Preparation

Module 1–5 compilation, gap analysis, and eCTD publishing — submission-ready for every target agency.

Learn More

DCGI & CDSCO Approvals

Clinical trial applications, BE-NOCs, test licences, and new drug approvals under the NDCT Rules, 2019.

Learn More

ANDA Dossiers

US FDA generic submissions with Module 3 CMC built by people who work with manufacturing daily.

Learn More

Discuss Your ANVISA / Brazil Requirement

Share your molecule and target market — our scientific team responds with a study design, timeline, and detailed proposal within 24 business hours.

Get a ProposalContact Us

Need something? Chat with us!